论文部分内容阅读
本文首次应用免疫组化ＰＡＰ法检测膀胱癌组织中的ＥＲ、ＰＲ（２８例）及β２－ＭＧ（３５例）的表达状况。结果表明：ＥＲ（＋）者１０例（３５．７％）、ＰＲ（＋）者８例（２８．６％），β２－ＭＧ（＋）者１５例（４２．９％）。肿瘤的组织分级和临床分期与ＥＲ、ＰＲ表达里正相关，与β２－ＭＧ的表达呈负相关，随访五年其复发率和死亡率ＥＲ（＋）者、ＰＲ（＋）者高于阴性者，β２－ＭＧ（＋）者低于阴性者。证明ＥＲ、ＰＲ存在于膀胱癌组织中，对诊断及预后的估计有一定的价值，并与β２－ＭＧ是二组相邀指标。认为对膀胱癌ＥＲ、ＰＲ阳性患者可试行辅助性内分泌治疗。
The immunohistochemical PAP method was used for the first time to detect the expression of ER, PR (28 cases) and β2-MG (35 cases) in bladder cancer. The results showed that there were 10 cases (35.7%) of ER (+), 8 cases (28.6%) of PR (+) and 15 cases (42.9%) of β2-MG (+). The tumor grade and clinical stage were positively correlated with ER and PR expression, but negatively correlated with the expression of β2-MG. The recurrence rate and mortality ER (+) and PR (+) were higher than those with negative , Β2-MG (+) were lower than those who were negative. It is proved that ER and PR exist in bladder cancer tissues, which have certain value in the diagnosis and prognosis estimation. They are also two indexes of β2-MG. Bladder cancer ER, PR-positive patients may try adjuvant endocrine therapy.